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Abstract For thousands of years, humans have
safely consumed microorganisms through fermented
foods. Many of these bacteria are considered probi-
otics, which act through diverse mechanisms to
confer a health benefit to the host. However, it was
not until the availability of whole-genome sequen-
cing and the era of genomics that mechanisms of
probiotic efficacy could be discovered. In this review,
we explore the history of the probiotic concept and the
current standard of integrated genomic techniques to
discern the complex, beneficial relationships between
probiotic microbes and their hosts.
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Introduction
History of probiotic bacteria and the probiotic
concept
A multitude of autochthonous (naturally occurring)
commensal bacterial species inhabit the mucosal
surfaces of the gastro-intestinal tract (GIT), as well
as those of the nose, mouth and vagina. It has long
been held that the consumption of allochthonous
(transient) beneficial bacteria, either through food
products or supplements, has a positive influence on
general health and well-being of the host via com-
mensal interactions with the GIT immune system and
resident microbiota. These beneficial microorganisms,
known as probiotics, are defined by the World Health
Organization as ‘‘live microorganisms, which when
administered in adequate amounts, confer a health
benefit upon the host’’ (FAO/WHO 2002). Over the
past four decades, there has been substantial research
in the field of probiotics and, more specifically, into
the mechanism of probiotic action within the host.
However, the probiotic concept is not novel to the
twentieth century and twenty-first centuries.
For millennia, humans have consumed microor-
ganisms via fermented foods, which served to prevent
putrefaction as well as increase sensory aspects in the
food. Some of the first fermentations were likely the
result of serendipitous contaminations in favourable
environments resulting in soured milk products such
as kefir, leben, koumiss, yogurt and sour cream—
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products that are still consumed worldwide (Hosono
1992). Furthermore, through the continued practice of
milk souring along with back slopping techniques,
humans inadvertently aided in the domestication of
certain microorganisms to diverse food environments
over time (Douglas and Klaenhammer 2010). Not only
were these products safe to consume, fermented dairy
foods were culturally significant, as evidenced by their
mention in the Bible and early sacred Hindu texts, as
well as therapeutically consumed (Hosono 1992; Bibel
1988; Shortt 1999).
In the late nineteenth century, French biochemist
Louis Pasteur premiered significant discoveries lead-
ing to a greater scientific understanding of fermenta-
tion (Fig. 1). Upon studying wine and beer
fermentations, Pasteur demonstrated that fermentation
reactions are carried out by microorganisms. Further-
more, he established that the growth of these microbes
is not a product of spontaneous generation, as was the
prevailing scientific and cultural consensus, but is
instead due to biogenesis, which posits that all living
things come only from other living things. On the
foundation of Pasteur’s research, Russian Nobel
laureate, E´lie Metchnikoff first popularized the con-
cept of probiotics around the turn of the twentieth
century. In his book, The Prolongation of Life:
Optimistic Studies, Metchnikoff (1907) proposed that
putrefaction in the intestines correlated with shortened
life expectancy. Reconciling long-held observations
involving lactic acid food fermentations with micro-
bial feeding studies in animals and humans, Metch-
nikoff proposed that lactic acid-producing
microorganisms may act as anti-putrefactive agents
in the gastrointestinal tract when consumed. In fact, he
hypothesized that by transforming the ‘‘wild popula-
tion of the intestine into a cultured population… the
pathological symptoms may be removed from old age,
and… in all probability, the duration of the life of man
may be considerably increased’’ (Metchnikoff 1907).
His theory was bolstered upon observing a higher
prevalence of centenarians in Bulgaria, a region
known for the consumption of soured milk. Michel
Cohendy, a colleague at the Pasteur Institute, provided
experimental data to support Metchnikoff’s hypothe-
sis. In two feeding trials of human subjects, Cohendy
found that the Bulgarian bacillus (now known as
Lactobacillus delbrueckii subsp. bulgaricus) was
recoverable from faeces; reduced the prevalence of
putrefactive toxins; and aided in the treatment of
colitis following transplantation to the large intestine
(Cohendy 1906a, b). The aforementioned studies on L.
bulgaricus enthralled the health-conscious society of
Europe in the early 20th century and soon the Pasteur
Institute of Paris began selling the Lactobacillus under
the label of ‘‘Le Ferment’’ (Shortt 1999; Bibel 1988).
Despite the promising observations made by
Metchnikoff and colleagues at the genesis of the
probiotic concept, there was still meager scientific
evidence suggesting any definitive probiotic strains or
their purported effector mechanisms. In fact, Leo
Rettger and coworkers at Yale University found that L.
bulgaricus could not survive gastric passage to
colonize the small intestine (Rettger 1915). This study
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Fig. 1 Seminal milestones contributing to the functional characterization of probiotic lactic acid bacteria
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present in the original therapeutic administration
studies performed by Cohendy, and subsequently sold
as ‘‘Le Ferment.’’ Instead, Lactobacillus acidophilus
was touted to be a more suitable candidate for
therapeutic applications because of its ability to
survive gastric passage and transform the intestinal
flora in conditions of lactose and dextrin supplemen-
tation (Rettger and Cheplin 1921). It is based on these
seminal studies that the foundation of therapeutic
treatment with L. acidophilus originated. However,
even rigorous studies such as these were limited by the
techniques and technologies of their time. L. acidoph-
ilus could not be distinguished from other aciduric
commensal lactobacilli, such as Lactobacillus gasseri,
until electrophoretic DNA–DNA hybridization studies
on Lactobacillus lactate dehydrogenase enzymes were
performed in the 1970s (Gasser 1970; Gasser et al.
1970). Therefore, it is unknown whether the cultures
administered during these studies were indeed pure L.
acidophilus, or mixed culture with L. acidophilus, L.
gasseri and other aciduric lactobacilli.
After examining the burgeoning experimental evi-
dence of probiotic bacteria, a Japanese physician
named Minoru Shirota sought to isolate a human-
derived strain of Lactobacillus for therapeutic appli-
cation. And thus, in 1930, Shirota selected a species of
Lactobacillus (now known as Lactobacillus casei
Shirota) from human faeces that could survive passage
through the GIT (Shortt 1999). From this culture,
Shirota developed and commercialized one of the first
fermented milk products, Yakult (Shortt 1999). Not
only was this a major advancement for the commercial
dairy industry, but one of the first products to deliver a
pure, defined strain-cultured product. Yakult remains a
staple product in Japanese, Korean, Australian and
European markets. Since then, there has been a
massive expansion of the functional food market,
especially in fermented dairy products containing
probiotic bacteria (Sanders and in’t Huis-Veld 1999).
In fact, a recent global market analysis on probiotics
revealed a 7 % annual growth during the 2012 fiscal
year, with a forecast of $48 billion in earnings within
the next 5 years (Global Industry Analysis Report
2012). Furthermore, probiotics are expanding from
functional food markets to pharmaceutical, therapeu-
tic markets. This market increase correlates to the
advancements of the scientific and regulatory aspects
of probiotic mechanisms and delivery (Foligne et al.
2013). Considering that there are still a great number
of scientific questions to explore concerning probiotic
activities and interactions in the GIT, there remains a
bright future for the field of probiotic research and the
market thereof.
Modern use of probiotic bacteria
Despite the long, storied history of probiotic discovery
and therapeutic application, resounding clinical and
experimental evidence for the use of probiotic bacteria
has only recently come to a head (Table 1). One
prominent example is the use of probiotics to treat
functional gastrointestinal disorders (FGID). For
many FGID, such as irritable bowel syndrome (IBS),
there are few pharmacological treatment options due
to low efficacy and serious side effects (Shen and
Nahas 2009). Furthermore, IBS is quite common and
is thought to be caused by changes in the gastrointes-
tinal microbiome (Porter et al. 2011). Recently, a
systematic review of successful clinical interventions
using probiotics to treat various FGID has been
compiled as a reference for clinicians to make
evidence-based treatment decisions (Hungin et al.
2013). This systematic analysis reflects a notable
caveat that must be made in probiotic research;
namely, that probiotic activities are strain-specific
(Hungin et al. 2013; Sanders et al. 2013). Because
evidence clearly suggests not only the efficacy of
probiotic therapy, but also the importance of under-
standing each strain, the paradigm of probiotic
research is rightfully shifting towards understanding
the mechanistic action of each specific strain.
Among the most studied species of probiotic
bacteria are those from the genera Lactobacillus and
Bifidobacterium (Table 2). The genus Lactobacillus is
comprised of a diverse clade of Gram-positive,
anaerobic/microaerophilic, non-sporulating, low
G ? C content lactic acid bacteria (LAB) belonging
to the phylum Firmicutes (Pot et al. 1994). Biochem-
ically, they are strictly fermentative; sugar fermenta-
tions result in either the sole production of lactic acid,
or the production of lactic acid in conjunction with
smaller amounts of carbon dioxide and ethanol/acetic
acid (Hammes and Vogel 1995; Pot et al. 1994).
Lactobacilli inhabit diverse ecological niches includ-
ing the GIT of humans and animals, as well as
vegetable, plant and dairy food environments. While
Lactobacillus species are not dominant members of
the colonic microbiotia, many are probiotic because of
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their ability to survive in the less-diverse small
intestine. Members of the genus Bifidobacterium, of
the phylum Actinobacteria, are Gram-positive, non-
motile, anaerobic bacteria, with low levels of genomic
and phylogenetic diversity (Ventura et al. 2006). They
were originally isolated from the faeces of breast-fed
infants (Tissier 1900) and nearly 50 species isolated
from the GIT of humans animals and insects have
since been classified (Velez et al. 2007). In fact,
bifidobacteria are among the most prominent com-
mensal bacteria found in the human colon and
dominate the developing microbiome in breast-fed
infants (Turroni et al. 2008; Favier et al. 2002).
Since the resolution of the first bacterial genome
sequence (Haemophilus influenzae), an exponential
advancement in sequencing processing, genome
assembly and annotation technologies, at increasingly
economical pricing, has yielded well over a thousand
publicly available genomes (Fleischmann et al. 1995;
Lagesen et al. 2010). Notably, many of these genomes
are derived from lactic acid bacteria used as probiotics
or starter cultures for food fermentations (Klaenham-
mer et al. 2002; Lukjancenko et al. 2012). Access to
these data has revolutionized the molecular view of
probiotic bacteria, as well as the way research
questions related to probiotic mechanisms are formu-
lated. Specifically, advancements in genomic tools
Table 1 Roles and benefits of probiotic bacteria in the GIT
Probiotic role/benefit Reference
Protection against infection Corr and O’Neill (2009)
Symptom relief from irritable
bowel syndrome
Hungin et al. (2013)




Lowered incidence of diarrhea Leyer et al. (2009)
Lowered risk of antibiotic-
associated diarrhea
Gao et al. (2010)
Lowered risk of C. dificile-
associated diarrhea
Plummer et al. (2004), Gao
et al. (2010)
Reduction in intestinal bloating Ringel-Kulka et al. (2011)
Abdominal pain analgesic (via
l-opiod and cannabinoid
receptors)
Rousseaux et al. (2007)
Lowered levels of cold and
influenza-like symptoms in
children
Leyer et al. (2009)
Antimicrobial activity Ryan et al. (2009)
Competitive exclusion of
pathogens
Lee et al. (2003)
Inhibition of H. pylori growth Ushiyama et al. (2003);
Fujimura et al. (2012)
Reduced incidence of
necrotizing enterocolitis
Deshpande et al. (2010)
Prevention of upper respiratory
infections
Hao et al. (2011)
Immune tolerance van Baarlen et al. (2009)
Reduction in colorectal cancer
biomarkers
Rafter et al. (2007)
Return to pre-antibiotic baseline
flora
Engelbrektson et al. (2009)
Epithelial barrier function Mennigen and Bruewer
(2009)




Increased humoral immunity via
secretion of IgA
Viljanen et al. (2005)
Lowered blood cholesterol levels Ataie-Jafari et al. (2009)
Reduction in irritable bowel
disease symptoms
MacFarlane et al. (2009)
Delivery of therapeutics Wells and Mercenier
(2008)
Modified from O’Flaherty and Klaenhammer (2010a)









Altermann et al. (2005)
(NC_006814.3)
L. casei (BL23) Maze et al. (2010) (NC_010999.1)
L. johnsonii (NCC
533)
Pridmore et al. (2004) (NC_ 005632.1)
L. plantarum
(JDM1)
Zhang et al. (2009) (NC_012984.1)
L. reuteri (SD2112) (NC_015697.1)





















Schell et al. (2002) (NC_004307.2)
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including functional genomics, transcriptomics, pro-
teomics and secretomics, have hastened research
deciphering the interactions between probiotics and
the GIT (Fig. 2). These techniques are being used to
bridge the mechanistic gap between what has been
seen clinically and anecdotally for hundreds of years.
Characterizing probiotic mechanisms using
genomic tools
Referencing the genome sequences of probiotic bac-
teria, the mechanism and interaction of probiotics with
the host GIT are being discovered through the
integration of functional genomic techniques. Within
this context, there are three points of focus relating to
probiotic action: (i) survival through gastrointestinal
transit and adhesion to intestinal epithelia; (ii)
competitive exclusion and antimicrobial activity; and
(iii) modulation of the host GIT immune system
(Fig. 3).
Survival in and adhesion to the GIT
One of the most essential qualities of a probiotic
microorganism is the ability to survive the varied
environments of the GIT (Fig. 3a). The probiotic must
be able to adapt to acidic gastric juices and bile in the
small intestine. Like many aciduric bacteria, the lipid
membranes of lactobacilli exposed to acid and bile are
altered in order to increase survival. The lipid
membrane of Lactobacillus casei demonstrated a
marked increase of mono-unsaturated fatty acids in
response to acidification (Fozo et al. 2004). Similarly,
the lipid membrane of Lactobacillus reuteri exposed
Proteomics Functional Genomics Transcriptomics
Functional characterization of probiotic-host interactions
Genome sequencing and mutational 
knockout analysis 
Analysis of proteins expressed, 
secreted, or attached to the cell wall 
Transcriptional responses of bacteria to 





Fig. 2 With the advent of genome sequencing, integrated
genomic techniques including proteomics, transcriptomics and
functional genomics have collectively characterized the mech-
anism of probiotic host-interactions. These analyses rely on
access to annotated sequence data from whole genome
sequencing. Genetic systems for deletions and mutational
knockouts allow for phenotyping specific genetic loci. Proteo-
mic approaches involve the characterization of proteins
expressed, secreted, and/or attached to the cell wall. In this
way, proteins are isolated, characterized by mass spectrometry,
and mapped back to the proteome and corresponding genome
for functional analysis. Finally, transcriptomic profiling using
DNA microarrays, RNA sequencing, and RT-qPCR can
measure the transcriptional responses of both bacteria and host
cells in response to one another, via measurement of mRNA
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to bile salts and cholesterol increased the number of
mono-unsaturated fatty acids compared to saturated
fatty acids (Taranto et al. 2003). Considering these
observations, a recent study using the probiotic
Lactobacillus rhamnosus GG found that an exogenous
oleic acid [C18:1 (cis-9)] source significantly
increased acid survival by incorporating the oleic acid
into the membrane, which is reduced to stearic acid
(C18:0) in the acidified environment (Corcoran et al.
2007). Aside from the biochemical changes to the lipid
membranes, the Lactobacillus species have global
transcriptional responses to these stressors, usually
through two-component regulatory systems (2CRS;
Lebeer et al. 2008b). Numerous transcriptomic anal-
yses have been used in lactobacilli to identify differ-
entially expressed genes, such as those corresponding
to 2CRS, surface proteins and proton efflux systems, in
response to gastric acid stress (Azcarate-Peril et al.
2005; Pieterse et al. 2005) and bile stress (Bron et al.
2006; Pfeiler et al. 2007). Bacteria quickly sense and
respond to changing environmental conditions via
2CRS through the sensing domains of a transmem-
brane histidine protein kinase (HPK). Upon receiving
the environmental signal, the HPK is activated to
autophosphorylate a specific histidine residue which is
transferred to the regulatory domain of the response
regulator (RR), a DNA-binding transcriptional regu-
lator. Therefore, 2CRS can be predicted from bacterial
genome sequence annotations based on the presence
of putative HPK and RR in close proximity to one
another (Altermann et al. 2005; Morita et al. 2009). In
L. acidophilus NCFM, a gene (lba1524) encoding a
functional HPK was knocked out, resulting in a mutant
with increased sensitivity to acid stress compared to
the parent strain. Furthermore, transcriptomic analysis
via DNA microarray comparing the lba1524 mutant to
wild-type demonstrated an impact on 80 genes (Azc-
arate-Peril et al. 2005). Notably, one upregulated gene
in the HPK mutant was the LuxS homolog of the
autoinducer-2 quorum sensing compound, important
for survival in gastric juices and adhesion to intestinal
epithelial cell lines (Lebeer et al. 2008a; Buck et al.
2009).
The response of lactobacilli to bile salts has also
been measured through microarray analysis. In Lacto-
bacillus plantarum a DNA-microarray was performed
after exposure to porcine bile, resulting in the identi-
fication of bile response genes encoding stress response
proteins, cell envelope proteins and an F0F1 ATPase
(Bron et al. 2006). A similar transcriptomic profiling of
L. acidophilus revealed multiple genes involved in bile
tolerance, including a 2CRS and multi-drug resistance
(MDR) transporter efflux pumps (Pfeiler et al. 2007).
Mutants with insertionally inactivated genes for the
bile inducible 2CRS HPK and RR were more sensitive
to bile compared to parent strains, confirming their role
in bile tolerance (Pfeiler et al. 2007). A recent
comparative proteomic analysis on bile sensitive and
Fig. 3 a Probiotic microbes delivered orally must survive
varying environments encountered through gastrointestinal
transit, including acidic gastric juices (pH *2) in the stomach,
and bile in the small intestines. b At the intestinal epithelia,
probiotics have been reported to adhere in high numbers,
leading to competitive exclusion of pathogens. The growth of
certain probiotics can be stimulated by the presence of complex
prebiotic oligosaccharides. Additionally, some probiotics pro-
duce bacteriocins and other antimicrobial agents which may
antagonize pathogens in the lumen. c Probiotics bound in the
mucus and epithelial layers are proximal to dendritic cells of the
mucosal immune system, leading to immunomodulation
146 Antonie van Leeuwenhoek (2014) 106:141–156
123
bile tolerant strains of L. plantarum corroborated these
transcriptomic data and elucidated potential biomark-
ers for the selection of bile tolerant probiotic strains
(Hao et al. 2011). Additionally, the role of efflux
pumps and MDR transporters in probiotic bile toler-
ance are beginning to be recognized. Functional
genomic analyses of MDR transporters in probiotic
strains of L. reuterii and L. acidophilus demonstrated
roles in bile tolerance (Whitehead et al. 2008; Pfeiler
and Klaenhammer 2009). Furthermore, a MDR trans-
porter gene in Bifidobacterium longum, betA (bile
efflux transporter), was recently identified through in
silico genome analysis and functionally characterized
(Gueimonde et al. 2009). Heterologous expression of
betA in Escherichia coli conferred bile tolerance
through active efflux of bile salts.
Survivability and enhancement of beneficial
microbes in the GIT can be accomplished by providing
selectively utilizable carbohydrates, called prebiotics
(Roberfroid 2007; Andersen et al. 2013). These
carbohydrates, including b-galactooligosaccharide
(GOS), lactulose, fructo-oligosaccharide and inulin,
are resistant to gastric acidity, hydrolysis and gastro-
intestinal absorption (Roberfroid et al. 2010). As
growth substrates, prebiotic carbohydrates are prefer-
entially metabolized by species of health-promoting
bacteria. Recently, differential transcriptomic and
functional genomic analyses have demonstrated the
capabilities of the probiotic bacteria L. acidophilus
NCFM (Andersen et al. 2012) and Bifidobacterium
lactis B1-04 (Andersen et al. 2013) to utilize prebiotic
oligosaccharides. With these data, novel symbiotic
formulations of corresponding prebiotics for L. aci-
dophilus and B. lactis can be created to aid in the
survival and probiotic effectiveness in the host small
intestines and colon, respectively. In a similar vein,
there is compelling evidence to suggest glycogen
metabolism is a colonization factor for probiotic LAB.
Glycogen is a large molecular mass, soluble a-1,4-
linked glucose polymer with numerous a-1,6-linked
branches. It has multiple physiological functions in
various bacteria and has been theorized to function as a
carbon capacitor for the regulation of energy flux
(Belanger and Hatfull 1999). Recent work by Goh and
Klaenhammer (2013) demonstrated the functionality
of a putative glycogen metabolism operon found in the
genome sequence. Remarkably, through a series of
chromosomal deletions and phenotypic assays, glyco-
gen metabolism was found to regulate growth
maintenance, bile tolerance and complex carbohydrate
utilization in L. acidophilus (Goh and Klaenhammer
2013).
Beyond surviving gastrointestinal transit, a second
key factor for probiotic activity is through adhesion
to intestinal epithelia of the GIT. Preliminary in vitro
studies using Caco-2 human intestinal epithelial cell
lines revealed multiple probiotic lactobacilli with
adhesive capabilities (Chauviere et al. 1992; Tuo-
mola and Salminen 1998). Notably, there has also
been work demonstrating the adhesiveness of Bifi-
dobacterium spp. to human intestinal mucus (He
et al. 2001). However, access to genome sequence
data, paired with integrated genomic techniques,
elucidated mediators of probiotic adhesion. The
majority of these factors are secreted or attached to
the cell wall in a sortase-dependent manner, in order
to interface with the intestinal epithelia (reviewed by
Velez et al. 2007 Lebeer et al. 2008b). In a study
using L. plantarum WCFS1, two of these sortase-
dependent proteins (SDP) were found to be induced
in the murine GIT (Bron et al. 2004a, b). Mutational
analysis of one of these genes (lp_2940) resulted in a
100- to 1,000-fold decrease in persistence capacity of
the L. plantarum lp_2940 knockout mutant in a
mouse model. In L. acidophilus NCFM, in silico
genome screening lead to the selection of five
putative adhesion cell surface proteins, including a
fibronectin binding protein (FbpA), S-layer protein
(SlpA), mucin-binding protein (Mub) and two R28
homologues involved in streptococcal adhesion
(Buck et al. 2005). Through mutational analysis,
FbpA, Mub, and SlpA were all found to contribute to
adhesion to Caco-2 epithelial cell lines. Similarly, a
stress response protein and an aggregation-promoting
factor (both cell surface proteins) were found in later
studies to contribute to adherence to Caco-2 cells
(O’Flaherty and Klaenhammer 2010b; Goh and
Klaenhammer 2010). In Lactobacillus crispatus
JCM5810, the S-layer protein (CbsA) contains
domains that bind to laminin and collagens (Anti-
kainen et al. 2002). Genome screening and secretome
analysis of Lactobacillus salivarius UCC118 led to
the identification of three SDPs with mucus-binding
domains. A sortase-deficient strain was created,
resulting in significantly reduced adherence to
Caco-2 and HT-29 cell lines in vitro (van Pijkeren
et al. 2006). Notably, genomic analysis between two
strains of L. rhamnosus revealed the presence of a
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genomic island in L. rhamnosus GG that contained
three secreted, sortase-dependent pilins encoded by
spaCBA (Kankainen et al. 2009). Immunoblotting
and immunogold electron microscopy confirmed the
formation of cell wall-bound pili (Fig. 4). Further-
more, mutational analysis of the spaC gene abolished
the adherence capability of L. rhamnosus GG to
human intestinal mucus, implicating the role of these
unique pili structures in adherence and retention in
the GIT. Since this initial report, a type IVb tight
adherence (Tad) pilus-encoding gene cluster has been
identified in Bifidobacterium breve UCC2003
(O’Connell Motherway et al. 2011; Fig. 4). Muta-
tional analysis demonstrated that the Tad gene cluster
was essential for colonization in a murine model.
Collectively, these data suggest that there are multi-
ple cell surface factors which contribute to probiotic
adherence to human intestinal epithelia.
Competitive exclusion and antimicrobial activity
Another health-promoting aspect of probiotic bacteria
is the prevention of pathogenic infection (Fig. 3b).
When probiotic lactobacilli are ingested, they tempo-
rarily coat the mucosal layer and epithelia of the small
intestine (see above) leading to both physical and
chemical barriers against harmful bacteria (Servin
2004). Initial studies demonstrated that lactobacilli
inhibited adherence of Gram-negative uropathogens
when uroepithelial cells were pre-incubated with
whole, viable Lactobacillus (Chan et al. 1985).
Furthermore, in vivo mice models demonstrated that
L. casei GR1 was capable of preventing urinary tract
infections from E. coli, Klebsiella pneumoniae, and
Pseudomonus aeruginosa (Reid et al. 1985). In both
cases, the mechanism of pathogenic antagonism was
due to the ability of lactobacilli to adhere to the
Fig. 4 Identification of pili structures in Lactobacillus rhamno-
sus GG (I) and Bifidobacterium breve UCC2003 (II). Images
were obtained using transmission electron microscopy on
negatively stained, immunogold-labeled anti-SpaC pili in L.
rhamnosus (I) and anti-Flp2003 pili in B. breve (II). Reprinted
with permission from Kankainen et al. (2009), copyright 2009
National Academy of Sciences, USA; and O’Connell Mother-
way et al. (2011), copyright  2011 National Academy of
Sciences USA
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urogenital epithelia, thus preventing infection through
competitive exclusion of the pathogen. These studies
and others suggested that similar competitive exclu-
sion could be possible in the human GIT using
probiotic lactobacilli and bifidobacteria. In fact,
numerous studies have demonstrated the in vitro
inhibition of numerous gastrointestinal pathogens
through competitive exclusion of probiotic lactobacilli
and bifidobacteria using intestinal cell lines (reviewed
by: Servin 2004).
In addition to competitive exclusion of pathogens,
probiotic bacteria produce numerous chemical antimi-
crobials which may prevent pathogenic infection.
These include: hydrogen peroxide (St Amant et al.
2002; Pridmore et al. 2008), lactic acid (Fayol-
Messaoudi et al. 2005), biosurfactants (Velraeds
et al. 1996), immunomodulatory products (Ryan
et al. 2009) and bacteriocins (Dobson et al. 2012).
Bacteriocins are bacterially derived antimicrobial
peptides that are active against other bacteria, but to
which the producing bacterium is immune (Cotter et al.
2005). Lactic acid bacteria produce numerous broad-
spectrum bacteriocins which are divided into three
main classes: class I bacteriocins (lantibiotics; Schnell
et al. 1988), small peptides possessing lanthionine
residues; class II bacteriocins, which are heat-stable
and do not contain lanthionine residues; and bacteri-
olysins, which are large, heat-labile murein hydrolases
(Cotter et al. 2005; Fig. 5). Historically, scientists have
sought to characterize the genetics and biochemistry of
bacteriocins produced by LAB, in part due to their
safety implications in the dairy fermentation industries
(Klaenhammer 1993; Nes et al. 1996). In fact, one of
the most industrially relevant bacteriocins is nisin, a
lantibiotic produced by Lactococcus lactis (Delves-
Broughton et al. 1996). Nisin has two modes of
bacteriocidal activity (Fig. 5). First, it can bind lipid II,
the main transporter of peptidoglycan subunits, dis-
rupting cell wall synthesis (Breukink et al. 1999). Nisin
also targets lipid II as a docking mechanism for pore
formation, leading to rapid cell death due to disruption
of the proton motive force (Wiedemann et al. 2001).
Notably, Gram-positive bacteriocins generally have a
narrow range of toxicity, as they are primarily lethal to
closely related bacterial species such as Staphylococ-
cus, Listeria and other LAB (Servin 2004). Most
research involving LAB-associated bacteriocins has
been in vitro. However, a landmark study by Corr et al.
(2007) demonstrated that a bacteriocin produced by L.
salivarius UCC118 caused in vivo protection in mice
challenged with the food-borne pathogen Listeria
monocytogenes. Using a functional genomics-based
mutational analysis, generating a stable L. salivarius
UCC118 strain deficient in bacteriocin production,
undoubtedly established the role of this bacteriocin in
protection against L. monocytogenes infection.
Probiotic modulation of the gastrointestinal
mucosal immune system
Perhaps one of the most important aspects of probiotic
bacteria is the ability to modulate the host GIT mucosal
immune system locally and systemically (Fig. 3c). The
interaction between the probiotic microbe with the
resident microbiota, gastrointestinal epithelia and gut
immune cells to produce an immunomodulatory
response is quite complex, and has been reviewed
exhaustively (Lebeer et al. 2010; O’Flaherty and
Klaenhammer 2010a; Reid et al. 2011; Bron et al.
2012; Klaenhammer et al. 2012; Selle and Klaenham-
mer 2013). Probiotic microbes modulate mucosal
immunity through the interaction of proteinacious
microorganism-associated molecular patterns
(MAMPs) with pattern recognition receptors (PRRs)
on antigen-presenting cells (APCs), such as dendritic
cells and macrophages. Upon exposure to MAMPs, the
PRRs (including NOD-like receptors, Toll-like recep-
tors, and C-type lectin receptors) activate nuclear
factor (NF)-jB and mitogen-activated protein kinase
signaling cascades, which modulate the expression of
cytokine and chemokine genes. The most common
MAMPs from probiotic microorganisms are lipotei-
choic acids (LTA), peptidoglycan and S-layer proteins
(Bron et al. 2012). Multiple studies have explored the
immunomodulatory effect of these MAMPs using
functional genomic techniques. In a seminal study, the
probiotics L. casei and L. reuteri were found to induce
IL-10 producing regulatory T-cells through the mod-
ulation of the DC-specific ICAM-3-grabbing noninte-
grin (DC-SIGN; Smits et al. 2005). Targeting of DC-
SIGN by probiotic bacteria is potentially an important
factor for treatment of inflammatory conditions via the
production of anti-inflammatory IL-10. The S-layer
protein (SlpA) of L. acidophilus NCFM was found to
bind DC-SIGN, which regulate immature DC and T
cell functionality (Konstantinov et al. 2008). Using L.
plantarum NCIMB8826, cell wall composition was
examined for immunomodulatory effects by creating a
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mutant (dlt -) which produced modified teichoic acids
with less D-alanine than the parent strain (Grangette
et al. 2005). The mutant demonstrated a significant
reduction in production of proinflammatory cytokines
compared to wild type, along with a simultaneous
increase in anti-inflammatory IL-10. Furthermore, the
dlt -mutant was more protective in an in vivo murine
colitis model than the parent strain (Grangette et al.
2005). An LTA-deficient strain of L. acidophilus
NCFM, created by a clean deletion of the lba0447
phosphoglycerol transferase, was able to abate induced
colonic-inflammation in a colitis mouse model through
the down regulation of pro-inflammatory IL-12 and
TNF-a and the up regulation of anti-inflammatory IL-
10 (Mohamadzadeh et al. 2011). Additionally, this
same mutant reduced colonic polyposis in a colon
cancer mouse model, through the normalization of
pathogenic immune responses (Khazaie et al. 2012).
Like many probiotic effectors, most MAMPs are
found on the cell surface of Gram-positive microbes.
Recently, the genomes and proteomes of several
lactobacilli were bioinformatically screened to create
a secretome database cataloging the various extracel-
lular proteins in LAB (Kleerebezem et al. 2010; Zhou
et al. 2010). Consequently, using in silico genome
analysis and by reference to the LAB secretome, a
putative MAMP can be selected and validated through
mutagenesis (Bron et al. 2012). Indeed, a recent study
of L. acidophilus used a proteomic-based method to
identify S-layer associated proteins (SLAPs) in situ
(Johnson et al. 2013). After extraction, the SLAPs
were identified through mass spectrometry and refer-
enced to the LAB secretome. Mutational analysis of
one SLAP (lba1029), revealed an immunomodulatory
phenotype using in vitro bacterial-DC co-incubation
assays, suggesting the potential of multiple unknown
Fig. 5 Bacteriocins
produced by LAB are
grouped into three classes
based on structure and
function: class I
(lantibiotics), class II, and
bacteriolysins. Class I
lantibiotics, such as nisin,
can have two modes of
action. First, they bind lipid
II to prevent peptidoglycan
subunit transport, disrupting
peptidoglycan synthesis and
cell division. Second, they
dock at lipid II to create
pores in the cytoplasmic
membrane of the bacteria.
Class II bacteriocins, such as
sakacin, often contain
amphiphilic helical
structures which can insert
into the cell membrane,
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MAMPs associated with the S-layer of L. acidophilus
NCFM. Researchers are also trying to understand the
complex dynamic of host-microbe crosstalk by using
whole transcriptome profiling of human intestinal
epithelia upon exposure to probiotics. In one study,
transcriptomes were obtained from the mucosa of the
proximal small intestines of healthy volunteers
exposed to probiotic L. acidophilus, L. casei, and L.
rhamnosus (van Baarlen et al. 2011). The transcrip-
tional networks induced by each probiotic were unique
to each strain and remarkably similar to response
profiles obtained from bioactive components and drug
treatments. In vitro transcriptome profiling of Caco-2
intestinal epithelial cell lines exposed to L. acidoph-
ilus NCFM corroborated these data (O’Flaherty and
Klaenhammer 2012). Similarly, Bifidobacterium bifi-
dum PRL2010 transcriptome analyses with both
in vitro human cell lines and in vivo murine models
demonstrated the capacity for strain PRL2010 to
modulate host innate immunity (Turroni et al. 2014).
Conclusions and future directions
While the paradigm of discovery based genomics in
probiotic LAB has uncovered vital aspects of probiotic
mechanisms, it has also revealed the complexity of
these interactions with the resident microbiota and the
mucosal immune system. But with this challenge has
come great opportunity. For example, probiotic bac-
teria are now being explored as suitable models for
vaccine/drug delivery, due to their close association
with host immunity and immunomodulatory action
(Kajikawa et al. 2011; Stoeker et al. 2011; Kajikawa
et al. 2012). Furthermore, recent discoveries are also
demonstrating that the roles of probiotic bacteria and
the resident microbiota extend far beyond gastrointes-
tinal health. Specifically, studies on the bi-directional
crosstalk between the GIT and the brain (the gut-brain
axis) are revealing the neurochemical importance of
gut homeostasis (Cryan and Mahony 2011; Bercik
et al. 2012). Along with these advancements, it is
important that human clinical trials continue with
experimental designs that are well-controlled and well-
defined, reflecting the great progress that has been
made in the field of probiotic and GIT microbiome
research (reviewed by Sanders et al. 2013). With more
than a century passing since Metchnikoff’s observa-
tions, keen experimental design using integrated
genomics has led to a clearer definition of probiotic
bacteria, as well as a model for continued discovery.
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